Pfizer Investor Presentation — July 2022

Document content

Breakthroughs that change patients' lives ®

July28, 2022Second Quarter 2022

Earnings TeleconferenceIntroduction

Senior Vice President,

Chief Investor Relations Officer3

Second Quarter 2022 EarningsForward -Looking Statements and Non- GAAP Financial Information

Our discussions during this conference call will include forward- looking statements that are subject to substantial risks and uncertainties that could cause actual results

to differ materially from those expressed or implied by such statements. We include forward- looking statements about, among other topics, our anticipated operating

and financial performance, reorganizations, business plans, strategy and prospects, our Environmental, Social and Governance (ESG) priorities and goals,

expectations for our product pipeline, in- line products and product candidates, including anticipated regulatory submissions, data read- outs, study starts, approvals,

clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potent ialbenefits, strategic reviews, capital

allocation objectives, dividends and share repurchases, plans for and prospects of our acquisitions, dispositions and other busi ness development activities, and our

ability to successfully capitalize on these opportunities, manufacturing and product supply, our efforts to respond to COVID -19,including Comirnaty and our oral

COVID -19 treatment ( Paxlovid ), our expectations regarding the impact of COVID -19 on our business, operations and financial results, and our Environmental, S ocial

and Governance strategy. Among other things, statements regarding revenue and earnings per share growth; the development or c omm ercial potential of our product

pipeline, in -line products, product candidates and additional indications, including expected clinical trial protocols, the timi ng of the initiation and progress of clinical trials